Investigation of the Survival Time of Patients Who Underwent Endovascular Treatment Due to Type 3 Aortic Dissection and Factors Affecting This Duration.

Objective: This study aimed to analyze the survival time of patients who underwent thoracic endovascular aortic replacement (TEVAR) due to acute type 3 aortic dissection and to investigate comorbid conditions and dissection characteristics that affect survival time. Materials and Methods: Between 2013 and 2023, 94 patients who underwent TEVAR for type 3 dissection were retrospectively investigated. Survival time and factors affecting this time (comorbidity and dissection characteristics) were analyzed. Results: The most common comorbidities were hypertension (88%). There was no significant difference between the demographic data of surviving and deceased patients. During the follow-up period, 57% of the patients survived, and 43% of the patients died. The mean survival time after TEVAR was 20.1 (0-108) months among patients who died and 47.7 (2-120) months for patients who lived. The mean number of comorbidities was 2.13 in patients who died and 2.25 in patients who survived. Survival distribution according to the type of interventional procedure was 50% for partial closure of the subclavian artery, 38.1% for complete closure, and 66.2% for closure starting from the distal subclavian artery ( Conclusion: In our study, the survival rate was higher in patients who were followed regularly, and reintervention was applied when necessary. Therefore, we believe that undetected or untreated complications after TEVAR, rather than comorbid conditions, negatively affect survival more.